Evidence map›Paper›PMID 40515658›Full record

ArticlePsychiatry and clinical neurosciences2025

Psychiatric-onset neuronal intranuclear inclusion disease in a psychiatry-based dementia-enriched cohort in Japan.

Tesshin Miyamoto, Kohji Mori, Shoshin Akamine, Shizuko Kondo, Shiho Gotoh, Ryota Uozumi, Sumiyo Umeda, Hanako Koguchi-Yoshioka, Satoshi Nojima, Daiki Taomoto and 6 more

Abstract read
In one paragraph

Article in Psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tesshin MiyamotoDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0009-0007-2195-6334
Kohji MoriDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0003-2629-0723
Shoshin AkamineDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0001-6476-6222
Shizuko KondoDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Shiho GotohDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-7068-4538
Ryota UozumiDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-1227-5082
Sumiyo UmedaDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0001-6572-7807
Hanako Koguchi-YoshiokaDepartment of Neurocutaneous Medicine, Division of Health Science, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-3415-5727
Satoshi NojimaDepartment of Pathology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-5124-0026
Daiki TaomotoDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0009-0006-0578-2517
Yuto SatakeDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-9350-3162
Takashi SuehiroDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Hideki KanemotoDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0003-3662-1469
Kenji YoshiyamaDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Takashi MoriharaDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0001-7371-6577
Manabu IkedaDepartment of Psychiatry, Graduate School of Medicine, The University of Osaka, Osaka, Japan.

Funding

AMED JP23bm0804034AMED JP23dk0207066JSPS KAKENHI JP22K19492JSPS KAKENHI JP24K02382JST FOREST Program JPMJFR200ZSENSHIN Medical Research FoundationTakeda Science FoundationThe Mochida Memorial Foundation for Medical and Pharmaceutical Research
6 · The paper itself

Abstract

aimA GGC repeat expansion in the 5' untranslated region of NOTCH2NLC is a genetic cause of Neuronal Intranuclear Inclusion Disease (NIID) that exhibits cognitive, motor, and autonomic dysfunction. Our objective is to determine whether there are undiagnosed NIID cases in a psychiatry-based dementia-enriched cohort and to identify their clinical characteristics.

methodsA retrospective clinical cohort study was conducted in an inpatient and outpatient psychiatric clinic in a University Hospital in Osaka, Japan. Genomic DNA and clinical information were collected with written informed consent. Nine hundred fifty-eight cases were clinically classified according to the International Classification of Diseases (ICD)-10 system. Genetic analysis with Repeat-Primed PCR and Amplicon-Length PCRs were performed.

resultsOf the 958 cases, three were confirmed to have an aberrant GGC repeat expansion in NOTCH2NLC. Cases 1 and 2 had preceding anxiety and depressive episodes, and one of these cases also had a mild cognitive impairment. Case 3 met the diagnostic criteria for progressive supranuclear palsy. All three cases lacked hyperintensity at the corticomedullary border on diffusion-weighted MRI, which is known as a characteristic for NIID. Interestingly, one case exhibited the corticomedullary hyperintensity later in the disease course with apparent neurocognitive decline. All three cases exhibited a mix of slow waves in electroencephalogram and elevated total protein level in cerebrospinal fluid.

conclusionsNIID is a rare cause of cognitive dysfunction in a psychiatry-based dementia-enriched cohort in Japan. Our data implicates psychiatric symptoms can be prodromal or early manifestation of a subset of NIID cases, thereby extending its phenotypic spectrum.

Indexed as

Cognitive DysfunctionDementiaNeurodegenerative DiseasesAgedAged, 80 and overCohort StudiesFemaleHumansIntercellular Signaling Peptides and ProteinsIntranuclear Inclusion BodiesJapanMaleMiddle AgedNerve Tissue ProteinsRetrospective StudiesTrinucleotide Repeat ExpansionIntercellular Signaling Peptides and ProteinsNerve Tissue ProteinsNOTCH2NLC protein, humanneurodegenerative diseaseNeuronal Intranuclear Inclusion DiseaseNOTCH2NLCrepeat diseaserepeat primed PCR

Identifiers

PMID40515658
PMCPMC12405813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.